Literature DB >> 10190696

Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis.

P A Calabresi1, R Martin, S Jacobson.   

Abstract

It is hypothesized that in MS and HTLV-1, chemokine and chemokine receptor expression are important mechanisms by which T cells migrate to sites of inflammation. Preliminary evidence supports the roles of several chemokines, including MIP 1beta, in mediating the enhanced migration capacity of MS derived PBLs. In addition, the ligand CCR-5 seems to be up regulated on PBLs from some MS patients. Analysis of T cell clones does not reveal a definite correlation between cytokine phenotype and chemokine receptor profile. The chemokines and chemokine receptor family are likely to be important molecules in chronic progressive neurological diseases, in which immune cells invade the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190696     DOI: 10.3109/13550289909029751

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  9 in total

1.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

2.  Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis.

Authors:  D J Mahad; S J L Howell; M N Woodroofe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 3.  Immune regulation of multiple sclerosis by CD8+ T cells.

Authors:  Sushmita Sinha; Farah R Itani; Nitin J Karandikar
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.

Authors:  Heike Wulff; Peter A Calabresi; Rameeza Allie; Sung Yun; Michael Pennington; Christine Beeton; K George Chandy
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

5.  CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population.

Authors:  Majid Shahbazi; Hamid Ebadi; Davood Fathi; Danial Roshandel; Mana Mahamadhoseeni; Azam Rashidbaghan; Narges Mahammadi; Mahammad Reza Mahammadi; Mahdi Zamani
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

6.  CCR5Δ32 Polymorphism Associated with a Slower Rate Disease Progression in a Cohort of RR-MS Sicilian Patients.

Authors:  Rosalia D'Angelo; Concetta Crisafulli; Carmela Rinaldi; Alessia Ruggeri; Aldo Amato; Antonina Sidoti
Journal:  Mult Scler Int       Date:  2011-06-23

Review 7.  Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications.

Authors:  Pushpalatha Palle; Kelly L Monaghan; Sarah M Milne; Edwin C K Wan
Journal:  Med Sci (Basel)       Date:  2017-10-13

Review 8.  CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis.

Authors:  Anna Pittaluga
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

Review 9.  Chemokines and viral diseases of the central nervous system.

Authors:  V C Asensio; I L Campbell
Journal:  Adv Virus Res       Date:  2001       Impact factor: 9.937

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.